Tafe Laura J, Muller Kristen E, Ananda Guruprasad, Mitchell Talia, Spotlow Vanessa, Patterson Sara E, Tsongalis Gregory J, Mockus Susan M
Department of Pathology, Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, New Hampshire; Department of Pathology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Department of Pathology, Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, New Hampshire; Department of Pathology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Am J Pathol. 2016 Mar;186(3):671-7. doi: 10.1016/j.ajpath.2015.11.008. Epub 2016 Jan 18.
Benign ovarian Brenner tumors often are associated with mucinous cystic neoplasms, which are hypothesized to share a histogenic origin and progression, however, supporting molecular characterization is limited. Our goal was to identify molecular mechanisms linking these tumors. DNA from six Brenner tumors with paired mucinous tumors, two Brenner tumors not associated with a mucinous neoplasm, and two atypical proliferative (borderline) Brenner tumors was extracted from formalin-fixed, paraffin-embedded tumor samples and sequenced using a 358-gene next-generation sequencing assay. Variant calls were compared within tumor groups to assess somatic mutation profiles. There was high concordance of the variants between paired samples (40% to 75%; P < 0.0001). Four of the six tumor pairs showed KRAS hotspot driver mutations specifically in the mucinous tumor. In the two paired samples that lacked KRAS mutations, MYC amplification was detected in both of the mucinous and the Brenner components; MYC amplification also was detected in a third Brenner tumor. Five of the Brenner tumors had no reportable potential driver alterations. The two atypical proliferative (borderline) Brenner tumors both had RAS mutations. The high degree of coordinate variants between paired Brenner and mucinous tumors supports a shared origin or progression. Differences observed in affected genes and pathways, particularly involving RAS and MYC, may point to molecular drivers of a divergent phenotype and progression of these tumors.
良性卵巢勃勒纳瘤常与黏液性囊性肿瘤相关,据推测二者具有共同的组织发生起源和进展过程,然而,支持这一观点的分子特征研究有限。我们的目标是确定连接这些肿瘤的分子机制。从福尔马林固定、石蜡包埋的肿瘤样本中提取了6例伴有配对黏液性肿瘤的勃勒纳瘤、2例不伴有黏液性肿瘤的勃勒纳瘤以及2例非典型增生性(交界性)勃勒纳瘤的DNA,并使用358基因的二代测序分析进行测序。在肿瘤组内比较变异位点,以评估体细胞突变谱。配对样本间变异位点的一致性较高(40%至75%;P<0.0001)。6对肿瘤中的4对显示KRAS热点驱动突变,且仅见于黏液性肿瘤。在2对缺乏KRAS突变的配对样本中,黏液性和勃勒纳成分均检测到MYC扩增;在第3例勃勒纳瘤中也检测到MYC扩增。5例勃勒纳瘤未发现可报告的潜在驱动改变。2例非典型增生性(交界性)勃勒纳瘤均有RAS突变。配对的勃勒纳瘤和黏液性肿瘤之间高度一致的变异支持了它们具有共同的起源或进展过程。在受影响的基因和通路中观察到的差异,特别是涉及RAS和MYC的差异,可能指向这些肿瘤不同表型和进展的分子驱动因素。